Inhibitors of human immunodeficiency virus type 1 derived from gp41 transmembrane protein: structure--activity...

Area of Science:

• Biochemistry
• Virology
• Medicinal Chemistry

Background:

• The gp41 protein is a critical component of the Human Immunodeficiency Virus type 1 (HIV-1) envelope.
• Understanding the structure-activity relationships of gp41 is essential for developing effective antiviral therapies.

Purpose of the Study:

• To synthesize and evaluate novel gp41 analogues for their inhibitory activity against HIV-1.
• To identify minimalistic gp41 fragments with potent antiviral properties.

Main Methods:

• Synthesis of gp41 analogues with varying N- and C-terminal truncations.
• Evaluation of inhibitory activity using MT4 cell assays.
• Chiral separation and assessment of diastereomeric conjugates.
• Circular dichroism studies to determine secondary structure.

Main Results:

• Truncation studies revealed that simultaneous N- and C-terminal truncation yielded a potent heptadecamer (13).
• Coupling with alpha-aminotetradecanoic acid (Atd) produced diastereomeric conjugates (e.g., 27 and 28) with differential inhibitory potencies, suggesting chiral interactions.
• Compounds 13 and 27 demonstrated potent HIV-1 inhibition, comparable to the original gp41 analogue.
• Circular dichroism indicated that the compounds maintain alpha-helical structures, likely contributing to their mechanism of action.

Conclusions:

• Minimalistic gp41 fragments, particularly heptadecamer 13 and pentadecamer 27, are potent inhibitors of HIV-1 replication.
• The findings support the impairment of viral gp41 as a viable mechanism for HIV-1 inhibition.
• These simplified analogues provide a foundation for designing next-generation gp41-based HIV-1 inhibitors.